Johnson & Johnson | Mega-cap | Healthcare
$152.39
0.25%
| Johnson & Johnson Stock Comparison:
Johnson & Johnson vs Eli Lilly andJohnson & Johnson vs AbbVieJohnson & Johnson vs Merck & CoJohnson & Johnson vs AmgenJohnson & Johnson vs Gilead SciencesJohnson & Johnson vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 88.8B
Gross Profit 61.4B 69.07%
Operating Income 22.1B 24.94%
Net Income 14.1B 15.84%
EPS (Diluted) $5.79

Balance Sheet Metrics

Total Assets 180.1B
Total Liabilities 108.6B
Shareholders Equity 71.5B
Debt to Equity 1.52

Cash Flow Metrics

Operating Cash Flow 22.5B
Free Cash Flow 18.1B

Revenue & Profitability Trend

Johnson & Johnson Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 88.8B 85.2B 80.0B 78.7B 82.6B
Cost of Goods Sold 27.5B 26.6B 24.6B 23.4B 28.4B
Gross Profit 61.4B 58.6B 55.4B 55.3B 54.2B
Operating Expenses 39.2B 35.2B 33.2B 34.4B 34.4B
Operating Income 22.1B 23.4B 22.2B 20.9B 19.7B
Pre-tax Income 16.7B 15.1B 19.4B 19.2B 16.5B
Income Tax 2.6B 1.7B 3.0B 1.4B 1.8B
Net Income 14.1B 35.2B 17.9B 20.9B 14.7B
EPS (Diluted) $5.79 $13.72 $6.73 $7.81 $5.51

Income Statement Trend

Johnson & Johnson Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 55.9B 53.5B 55.3B 61.0B 51.2B
Non-Current Assets 124.2B 114.1B 132.1B 121.0B 123.7B
Total Assets 180.1B 167.6B 187.4B 182.0B 174.9B
Liabilities
Current Liabilities 50.3B 46.3B 55.8B 45.2B 42.5B
Non-Current Liabilities 58.3B 52.5B 54.8B 62.8B 69.1B
Total Liabilities 108.6B 98.8B 110.6B 108.0B 111.6B
Equity
Total Shareholders Equity 71.5B 68.8B 76.8B 74.0B 63.3B

Balance Sheet Composition

Johnson & Johnson Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 14.1B 35.2B 17.9B 20.9B 14.7B
Operating Cash Flow 22.5B 40.3B 19.3B 20.6B 18.2B
Investing Activities
Capital Expenditures -4.4B -4.5B -4.0B -3.7B -3.3B
Investing Cash Flow -16.8B 1.3B -12.4B -8.7B -20.8B
Financing Activities
Dividends Paid -11.8B -11.8B -11.7B -11.0B -10.5B
Financing Cash Flow -13.4B -39.9B -16.8B -16.3B -9.9B
Free Cash Flow 18.1B 17.8B 17.2B 19.8B 20.2B

Cash Flow Trend

Johnson & Johnson Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 16.83
Forward P/E 14.28
Price to Book 4.66
Price to Sales 4.08
PEG Ratio 14.28

Profitability Ratios

Profit Margin 24.42%
Operating Margin 29.41%
Return on Equity 29.45%
Return on Assets 7.77%

Financial Health

Current Ratio 1.26
Debt to Equity 66.90
Beta 0.41

Per Share Data

EPS (TTM) $8.99
Book Value per Share $32.47
Revenue per Share $37.11

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
jnj 364.1B 16.83 4.66 29.45% 24.42% 66.90
Eli Lilly and 691.8B 62.76 46.33 77.28% 22.67% 243.61
AbbVie 324.6B 78.87 228.56 88.40% 7.31% 4,789.60
Merck & Co 198.5B 11.49 4.12 39.29% 27.27% 71.99
Amgen 146.5B 24.84 23.60 105.67% 17.39% 924.46
Gilead Sciences 132.1B 22.31 6.90 32.65% 20.76% 130.79

Financial data is updated regularly. All figures are in the company's reporting currency.